Cytotoxic effects of cladribine and tezacitabine toward HL-60

Acta Biochimica Polonica

Volumn 52, Issue 2, 2005, Pages 561-565

  Stachnik, Krzysztof ^a   Grieb, Paweł ^b   Skierski, Janusz S ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Cladribine; flow cytometry; HL 60 cells; Leukemia; Nucleoside analogs; Tezacitabine

Indexed keywords

EID: 23644445985     PISSN: 0001527X     EISSN: None     Source Type: Journal    
DOI: 10.18388/abp.2005_3474     Document Type: Article

References (24)

1. Cohen JD, Strock DJ, Teik JE, Katz TB, Marcel PD (1997) Cancer Lett 116: 1671-1675.
2. Faderl S, Garcia-Manero G, Thomas DA, Cortes J, O'Brien S, Giles FJ, Koller CA, Beran M, Verstovsek S, Kwari M, Ghandi V, Plunkett W, Kantarjian HM (2001) Blood 98: 2493.
3. Faderl S, Gandhi V, Kantarjian H, Plunkett W (2002) In Cancer Chemot Biol Resp Mod. Ann 20. Giaccone G, Schilsky R, Sondel P, eds, pp 37-58. Elsevier Science B.V.
4. Flaherty KT, Stevenson JP, Gallagher M, Giantonio B, Algazy KM, Sun W, Haller DG, O'Dwyer PJ (2003) Cancer 97: 1985-1990.
5. Galmarini CM, Mackey JR, Dumontet C (2001) Leukemia 15: 875-890.
6. Grieb P, Koronkiewicz M, Skierski JS (2000) Acta Biochim Polon 47: 165-171.
7. Grieb P, Kamienowski J, Janisz M, Kusnierczyk P, Kawiak J, Hoser G, Chrapusta SJ (2001) Int J Hematol 74: 421-427.
8. Gollard R, Miller WE, Piro LD, Saven A (1997) Leuk Lymphoma 28: 183-185.
9. Griffig J, Koob R, Blakley RL (1989) Cancer Res 49: 6923-6928.
10. Karlsson K, Stromberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A, Kimby E, Larfars G, Cristiansen I, Nilsson G, et al. (2002) Br J Haematol 116: 538-548.
11. Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D (1999) Haematologica 84: 22-25.
12. Liliemark J (1997) Clin Pharmacokinet 32: 120-131.
13. Liliemark J, Juliusson G (1995) Clin Cancer Res 1: 385-390.
14. McCarthy JR, Matthews DP, Stemerick DM, Huber EW, Bey P, Lippert BJ, Snyder RD, Sunkara P (1991) J Am Chem Soc 113: 7439-7440.
15. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. (1991) J Natl Cancer Inst 83: 757-766.
16. Piro LD, Carrera CJ, Carson DA, Beutler E (1990) N Engl J Med 322: 1117-1121.
17. Robak T, Gora-Tybor J, Krykowski E, Walewski JA, Borawska A, Pluzanska A, Potemski P, Hellmann A, Zaucha JM, Konopka L, et al (1997) Leuk Lymphoma 26: 99-105.
18. Robak T, Blasinska-Morawiec M, Blonski J, Hellmann A, Halaburda K, Konopka L, Kotlarek-Haus S, Potoczek S, Hansz J, Dmoszynska A, et al. (1999) Eur J Haematol 62: 49-56.
19. Rodriguez GI, Jones RE, Orenberg EK, Stoltz ML, Brooks DJ (2002) Clin Cancer Res 8: 2828-2834.
20. Ross DD, Joneckis CC, Ordonez JV, Sisk AM, Wu RK, Hamburger AW, Nora RE (1989) Cancer Res 49: 3776-3782.
21. Saven A, Piro LD (1994) Ann Intern Med 120: 784-791.
22. Seley KL (2000) Curr Opin Investig Drugs 1: 135-140.
23. Skierski JS, Koronkiewicz M, Grieb P (1999) Cytometry 37: 302-307.
24. Takahashi T, Nakashima A, Kanazawa J, Yamaguchi K, Akinaga S, Tamaoki T, Okabe M (1998) Cancer Chemother Pharmacol 41: 268-274.